<code id='C18FF34FD6'></code><style id='C18FF34FD6'></style>
    • <acronym id='C18FF34FD6'></acronym>
      <center id='C18FF34FD6'><center id='C18FF34FD6'><tfoot id='C18FF34FD6'></tfoot></center><abbr id='C18FF34FD6'><dir id='C18FF34FD6'><tfoot id='C18FF34FD6'></tfoot><noframes id='C18FF34FD6'>

    • <optgroup id='C18FF34FD6'><strike id='C18FF34FD6'><sup id='C18FF34FD6'></sup></strike><code id='C18FF34FD6'></code></optgroup>
        1. <b id='C18FF34FD6'><label id='C18FF34FD6'><select id='C18FF34FD6'><dt id='C18FF34FD6'><span id='C18FF34FD6'></span></dt></select></label></b><u id='C18FF34FD6'></u>
          <i id='C18FF34FD6'><strike id='C18FF34FD6'><tt id='C18FF34FD6'><pre id='C18FF34FD6'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:focus    - browse:7189
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot